News from anthera pharmaceuticals A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 04, 2010, 16:15 ET

Anthera Pharmaceuticals Reports 2010 Second Quarter Results

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced financial results and business highlights for the second quarter ended June 30,...

Jul 29, 2010, 08:30 ET

Anthera Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 - A Subcutaneous Dual Inhibitor of Membrane and Soluble B-Cell Activating Factor (BAFF or BLyS)

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...

Jul 27, 2010, 14:00 ET

Anthera Announces Second Quarter 2010 Financial Report and Conference Call

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...

Jun 23, 2010, 09:00 ET

Anthera Enrolls First Patients in Pivotal Varespladib Phase 3 Clinical Study

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation...

Jun 10, 2010, 14:42 ET

Anthera Pharmaceuticals Updates Its Lupus Scientific Advisory Board

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing therapeutics to treat serious diseases associated with...

Jun 03, 2010, 17:00 ET

Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing therapeutics to treat serious diseases associated with...

May 06, 2010, 16:15 ET

Anthera Issues First Quarter 2010 Financial Report

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today issued its first quarter 2010 financial report. Financial Results Total operating expenses...

May 03, 2010, 08:00 ET

Anthera Pharmaceuticals Announces Additional Data from FRANCIS Study

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...

Apr 28, 2010, 17:00 ET

Anthera Announces First Quarter 2010 Financial Report and Conference Call

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...

Apr 26, 2010, 17:00 ET

Anthera Pharmaceuticals to Present at Deutsche Bank Securities' 35th Annual Health Care Conference

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...

Apr 06, 2010, 17:00 ET

Anthera Pharmaceuticals Announces Closing of Underwriters' Exercise of Over-Allotment Option in Connection With Its Initial Public Offering

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...

Mar 23, 2010, 17:00 ET

Anthera Pharmaceuticals Welcomes Georgina Kilfoil as Senior Vice President of Product Development and Clinical Operations

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...

Mar 04, 2010, 16:30 ET

Anthera Pharmaceuticals Completes Initial Public Offering

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...

Feb 08, 2010, 07:00 ET

Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation,...

May 06, 2009, 07:00 ET

Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome

- Favorable results for secondary endpoints support outcomes benefit Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company...

Mar 24, 2009, 07:00 ET

Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after...

Nov 11, 2008, 07:00 ET

Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced new data on its lead...

Apr 17, 2008, 01:00 ET

Anthera Presents Data on Varespladib at ATVB Meeting

SAN MATEO, Calif., April 17 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing...

Apr 16, 2008, 01:00 ET

DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

SAN MATEO, Calif., April 16 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing...

Feb 07, 2008, 00:00 ET

Data From Anthera's Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions

SAN MATEO, Calif., Feb. 7 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory...